SCHEMBL5876867

SCHEMBL5876867

COc1ccc(C2(c3ccccc3)C=Cc3c(N)nn(S(=O)(=O)c4ccc(C)cc4)c3C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
KMT2A Q03164 7/20 0.47
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 3/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 3/20 0.41
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CXCL8 P10145 1/20 0.38
NOD1 Q9Y239 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 2/20 0.38
HSD11B1 P28845 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
GBA1 P04062 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876548 0.96 MAPT (0.50) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5875992 0.92 ALDH1A1 (0.41) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5877152 0.92 MAPT (0.41) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5877161 0.90 MAPT (0.40) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL5878036 0.89 NOD2 (0.41) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5876382 0.89 KMT2A (0.42) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5875943 0.88 ALDH1A1 (0.38) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5876154 0.88 MAPT (0.43) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5877548 0.87 MAPT (0.42) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5876602 0.87 MAPT (0.41) MAPTKMT2AALDH1A1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAPT 1879/4885KMT2A 2326/4885ALDH1A1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.